Gastric Cancer Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The gastric cancer market was valued at USD 4.70 Billion in 2024 , driven by growth in clinical trials and research across the 8 major markets. The market is expected to grow at a CAGR of 12.63% during the forecast period of 2025-2034, with the values likely to reach USD 15.44 Billion by 2034 .
Gastric Cancer Market Overview
Gastric or stomach cancer refers to a cancerous growth that occurs in the cells lining the stomach. It ranks as the third leading cause of cancer deaths and is estimated to be the fifth most frequently diagnosed cancer . Factors such as aging populations, especially in countries in Japan, and the rising lifestyle-related risks such as diet and smoking are contributing to the growing incidence of gastric cancer, which propels the market demand for effective treatments. The rising development of advanced treatment options like immunotherapies and minimally invasive surgical techniques supports the market growth. Further, the shift towards personalized medicine driven by advancements in genomics and molecular biology is anticipated to influence the market dynamics significantly.
Gastric Cancer Market Growth Drivers
Increasing Prevalence of Gastric Cancer Drives Market Growth
According to the American Cancer Society, around 26,890 new cases of stomach cancer and approximately 10,880 cases of deaths are estimated to occur in the United States in 2024. Further, stomach cancer is reported to account for 1.5% of all new cancer cases diagnosed in the United States annually. Recent data suggests that older adults are at a high risk of developing stomach cancer, with about 6 in every 10 individuals diagnosed with this cancer falling in the age category of 65 or above. Thus, the substantial burden of gastric cancer along with the increasing aging population is expected to drive the market growth in the coming years.
Gastric Cancer Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Shift Toward Personalized Medicine to Affect the Market Landscape Significantly
One of the major market trends is the shift towards personalized medicine to treat gastric cancer. This treatment approach is based on the genetic and molecular profile of a patient's tumor, which allows for more precise and effective interventions. In addition, companion diagnostics are increasingly being utilized to decide which patients are most likely to benefit from these targeted treatments. This not only optimizes treatment outcomes but also minimizes unnecessary side effects.
Rise in Investments Poised to Elevate Gastric Cancer Market Value
In July 2024, United Kingdom-based Myricx Bio, a European academic biotech spinout, secured EUR 90 million in a Series A financing round to support the clinical development of novel antibody-drug conjugates (ADCs) treatments for various types of tumors, including gastric cancer. Such substantial investment initiatives to advance gastric cancer treatments are poised to bolster the market growth in the forecast period.
Adoption of Combination Therapies Likely to Boost the Gastric Cancer Market Demand
A significant market trend is the rising preference for combination therapies in the management of gastric cancer. This treatment approach uses multiple therapies (such as chemotherapy, immunotherapy, and targeted drug therapy) either at the same other or sequentially to improve treatment efficacy. As the ongoing research studies and clinical trials continue to indicate improved survival rates and better patient outcomes for combination therapies, their adoption is likely to grow in the market in the forecast period.
Increased Focus on Immunotherapy to Boost Gastric Cancer Market Size
The market is witnessing a growing focus on immunotherapy as a treatment option for gastric cancer, particularly in patients with advanced or metastatic disease. Checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, are increasingly being adopted due to their ability to trigger the body's immune system to fight cancer. Moreover, increased research and clinical trials are expected to expand the use of immunotherapy for treating the earlier stages of the disease.
Gastric Cancer Market Segmentation
Market Breakup by Treatment Type
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, surgery, targeted drug therapy, and others. The chemotherapy segment represents a significant share of the market as this treatment finds its application across various stages of gastric cancer. Chemotherapy is often recommended as a first-line treatment, either alone or in combination with other therapies such as surgery and targeted drug therapy. It can help in shrinking tumors before surgery and also can manage symptoms in advanced stages of cancer and thus, is one of the most commonly utilized treatment options in the market.
Gastric Cancer Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a major market share for gastric cancer, owing to the high prevalence of the disease and advanced healthcare infrastructure. The robust research and development activities directed at finding innovative therapies for gastric cancer further aid the market growth in the region._x000D__x000D_
Additionally, the presence of key pharmaceutical companies and substantial demand for advanced treatment modalities such as immunotherapy and targeted drug therapies contribute to the expansion of the market. Moreover, the increasing investment in cancer research by both the United States government and private sectors is poised to fuel the growth and innovation in the market in the forecast period.
Leading Players in the Gastric Cancer Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca
AstraZeneca, a global research-based biopharmaceutical firm, has a prominent presence in the market. The company boasts a diverese portfolio of oncology drugs that target different aspects of cancer growth and progression. AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) in combination with chemotherapy is being investigated for its effectiveness in treating gastric cancer.
Pfizer, Inc.
Pfizer, Inc., headquartered in New York, United States, is a major market player focused on expanding its oncology portfolio. The company is actively engaged in exploring innovative treatments that address various cancer types, including gastric cancer. Pfizer has several ongoing clinical trials to investigate the efficacy of new treatment combinations and to expand the indications of its existing oncology drugs.
Novartis AG
Pharmaceutical corporation Novartis AG, based in Basel, Switzerland, is one of the leading companies in the market. The company is investing heavily in developing new therapies for gastric cancer including drugs that target specific molecular pathways involved in cancer growth.
Other key players in the market include Amgen Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Celltrion, AbbVie Inc., and GSK plc.
Key Questions Answered in the Gastric Cancer Market Report
Gastric Cancer Market Overview
Gastric or stomach cancer refers to a cancerous growth that occurs in the cells lining the stomach. It ranks as the third leading cause of cancer deaths and is estimated to be the fifth most frequently diagnosed cancer . Factors such as aging populations, especially in countries in Japan, and the rising lifestyle-related risks such as diet and smoking are contributing to the growing incidence of gastric cancer, which propels the market demand for effective treatments. The rising development of advanced treatment options like immunotherapies and minimally invasive surgical techniques supports the market growth. Further, the shift towards personalized medicine driven by advancements in genomics and molecular biology is anticipated to influence the market dynamics significantly.
Gastric Cancer Market Growth Drivers
Increasing Prevalence of Gastric Cancer Drives Market Growth
According to the American Cancer Society, around 26,890 new cases of stomach cancer and approximately 10,880 cases of deaths are estimated to occur in the United States in 2024. Further, stomach cancer is reported to account for 1.5% of all new cancer cases diagnosed in the United States annually. Recent data suggests that older adults are at a high risk of developing stomach cancer, with about 6 in every 10 individuals diagnosed with this cancer falling in the age category of 65 or above. Thus, the substantial burden of gastric cancer along with the increasing aging population is expected to drive the market growth in the coming years.
Gastric Cancer Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Shift Toward Personalized Medicine to Affect the Market Landscape Significantly
One of the major market trends is the shift towards personalized medicine to treat gastric cancer. This treatment approach is based on the genetic and molecular profile of a patient's tumor, which allows for more precise and effective interventions. In addition, companion diagnostics are increasingly being utilized to decide which patients are most likely to benefit from these targeted treatments. This not only optimizes treatment outcomes but also minimizes unnecessary side effects.
Rise in Investments Poised to Elevate Gastric Cancer Market Value
In July 2024, United Kingdom-based Myricx Bio, a European academic biotech spinout, secured EUR 90 million in a Series A financing round to support the clinical development of novel antibody-drug conjugates (ADCs) treatments for various types of tumors, including gastric cancer. Such substantial investment initiatives to advance gastric cancer treatments are poised to bolster the market growth in the forecast period.
Adoption of Combination Therapies Likely to Boost the Gastric Cancer Market Demand
A significant market trend is the rising preference for combination therapies in the management of gastric cancer. This treatment approach uses multiple therapies (such as chemotherapy, immunotherapy, and targeted drug therapy) either at the same other or sequentially to improve treatment efficacy. As the ongoing research studies and clinical trials continue to indicate improved survival rates and better patient outcomes for combination therapies, their adoption is likely to grow in the market in the forecast period.
Increased Focus on Immunotherapy to Boost Gastric Cancer Market Size
The market is witnessing a growing focus on immunotherapy as a treatment option for gastric cancer, particularly in patients with advanced or metastatic disease. Checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, are increasingly being adopted due to their ability to trigger the body's immune system to fight cancer. Moreover, increased research and clinical trials are expected to expand the use of immunotherapy for treating the earlier stages of the disease.
Gastric Cancer Market Segmentation
Market Breakup by Treatment Type
- Chemotherapy
- Immunotherapy
- Surgery
- Targeted Drug Therapy
- Others
- Adenocarcinoma
- Gastrointestinal Stromal Tumor
- Carcinoid Tumor
- Others
- Oral
- Parenteral
- Others
- Hospitals & Clinics
- Diagnostic Centers
- Research Laboratories
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into chemotherapy, immunotherapy, surgery, targeted drug therapy, and others. The chemotherapy segment represents a significant share of the market as this treatment finds its application across various stages of gastric cancer. Chemotherapy is often recommended as a first-line treatment, either alone or in combination with other therapies such as surgery and targeted drug therapy. It can help in shrinking tumors before surgery and also can manage symptoms in advanced stages of cancer and thus, is one of the most commonly utilized treatment options in the market.
Gastric Cancer Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a major market share for gastric cancer, owing to the high prevalence of the disease and advanced healthcare infrastructure. The robust research and development activities directed at finding innovative therapies for gastric cancer further aid the market growth in the region._x000D__x000D_
Additionally, the presence of key pharmaceutical companies and substantial demand for advanced treatment modalities such as immunotherapy and targeted drug therapies contribute to the expansion of the market. Moreover, the increasing investment in cancer research by both the United States government and private sectors is poised to fuel the growth and innovation in the market in the forecast period.
Leading Players in the Gastric Cancer Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca
AstraZeneca, a global research-based biopharmaceutical firm, has a prominent presence in the market. The company boasts a diverese portfolio of oncology drugs that target different aspects of cancer growth and progression. AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) in combination with chemotherapy is being investigated for its effectiveness in treating gastric cancer.
Pfizer, Inc.
Pfizer, Inc., headquartered in New York, United States, is a major market player focused on expanding its oncology portfolio. The company is actively engaged in exploring innovative treatments that address various cancer types, including gastric cancer. Pfizer has several ongoing clinical trials to investigate the efficacy of new treatment combinations and to expand the indications of its existing oncology drugs.
Novartis AG
Pharmaceutical corporation Novartis AG, based in Basel, Switzerland, is one of the leading companies in the market. The company is investing heavily in developing new therapies for gastric cancer including drugs that target specific molecular pathways involved in cancer growth.
Other key players in the market include Amgen Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Celltrion, AbbVie Inc., and GSK plc.
Key Questions Answered in the Gastric Cancer Market Report
- What was the gastric cancer market value in 2024?
- What is the gastric cancer market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on cancer type?
- What is the market breakup by route of administration?
- Who are the major end users in the market?
- What are the major factors aiding the gastric cancer market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of gastric cancer affect the market landscape?
- What are the major gastric cancer market trends?
- How does the growth in clinical trials impact the market size?
- Which treatment type will dominate the market share?
- Which cancer type is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the gastric cancer market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Gastric Cancer Market Overview – 8 Major Markets
- 3.1 Gastric Cancer Market Historical Value (2018-2024)
- 3.2 Gastric Cancer Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Gastric Cancer Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Gastric Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Gastric Cancer Market Landscape – 8 Major Markets
- 8.1 Gastric Cancer Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Gastric Cancer Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Cancer Type
- 8.2.3 Analysis by Route of Administration
- 9 Gastric Cancer Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Gastric Cancer Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Gastric Cancer Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Gastric Cancer Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Immunotherapy
- 12.1.4 Surgery
- 12.1.5 Targeted Drug Therapy
- 12.1.6 Others
- 12.2 Gastric Cancer Market (2018-2034) by Cancer Type
- 12.2.1 Market Overview
- 12.2.2 Adenocarcinoma
- 12.2.3 Gastrointestinal Stromal Tumor
- 12.2.4 Carcinoid Tumor
- 12.2.5 Others
- 12.3 Gastric Cancer Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Gastric Cancer Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals & Clinics
- 12.4.3 Diagnostic Centers
- 12.4.4 Research Laboratories
- 12.4.5 Others
- 12.5 Gastric Cancer Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Gastric Cancer Market (218-2034)
- 13.1 United States Gastric Cancer Market Historical Value (2018-2024)
- 13.2 United States Gastric Cancer Market Forecast Value (2025-2034)
- 13.3 United States Gastric Cancer Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Immunotherapy
- 13.3.4 Surgery
- 13.3.5 Targeted Drug Therapy
- 13.3.6 Others
- 13.4 United States Gastric Cancer Market (2018-2034) by Cancer Type
- 13.4.1 Market Overview
- 13.4.2 Adenocarcinoma
- 13.4.3 Gastrointestinal Stromal Tumor
- 13.4.4 Carcinoid Tumor
- 13.4.5 Others
- 13.5 United States Gastric Cancer Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 United States Gastric Cancer Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals & Clinics
- 13.6.3 Diagnostic Centers
- 13.6.4 Research Laboratories
- 13.6.5 Others
- 14 EU-4 and United Kingdom Gastric Cancer Market (218-2034)
- 14.1 EU-4 and United Kingdom Gastric Cancer Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Gastric Cancer Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Immunotherapy
- 14.3.4 Surgery
- 14.3.5 Targeted Drug Therapy
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by Cancer Type
- 14.4.1 Market Overview
- 14.4.2 Adenocarcinoma
- 14.4.3 Gastrointestinal Stromal Tumor
- 14.4.4 Carcinoid Tumor
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals & Clinics
- 14.6.3 Diagnostic Centers
- 14.6.4 Research Laboratories
- 14.6.5 Others
- 15 Japan Gastric Cancer Market
- 15.1 Japan Gastric Cancer Market Historical Value (2018-2024)
- 15.2 Japan Gastric Cancer Market Forecast Value (2025-2034)
- 15.3 Japan Gastric Cancer Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Immunotherapy
- 15.3.4 Surgery
- 15.3.5 Targeted Drug Therapy
- 15.3.6 Others
- 15.4 Japan Gastric Cancer Market (2018-2034) by Cancer Type
- 15.4.1 Market Overview
- 15.4.2 Adenocarcinoma
- 15.4.3 Gastrointestinal Stromal Tumor
- 15.4.4 Carcinoid Tumor
- 15.4.5 Others
- 15.5 Japan Gastric Cancer Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Japan Gastric Cancer Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals & Clinics
- 15.6.3 Diagnostic Centers
- 15.6.4 Research Laboratories
- 15.6.5 Others
- 16 India Gastric Cancer Market
- 16.1 India Gastric Cancer Market Historical Value (2018-2024)
- 16.2 India Gastric Cancer Market Forecast Value (2025-2034)
- 16.3 India Gastric Cancer Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Immunotherapy
- 16.3.4 Surgery
- 16.3.5 Targeted Drug Therapy
- 16.3.6 Others
- 16.4 India Gastric Cancer Market (2018-2034) by Cancer Type
- 16.4.1 Market Overview
- 16.4.2 Adenocarcinoma
- 16.4.3 Gastrointestinal Stromal Tumor
- 16.4.4 Carcinoid Tumor
- 16.4.5 Others
- 16.5 India Gastric Cancer Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 India Gastric Cancer Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals & Clinics
- 16.6.3 Diagnostic Centers
- 16.6.4 Research Laboratories
- 16.6.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Cancer Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 AstraZeneca
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Pfizer, Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 Novartis AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Amgen Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Bristol-Myers Squibb Company
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Eli Lily and Company
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Celltrion
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 AbbVie Inc
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 GSK plc
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 24 Gastric Cancer Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
